TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed
TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up!
In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed a paradigm shift due to the launch of various new drugs (Jevtana, Zytiga, Xtandi, Provenge). There are also a number of new candidates in late stage development to hit this market through different pathways. In the pipeline (Table 2), ~4 drugs are in late stage clinical development to compete against both these molecules (TAK-700, TOK-001, ODM-021, ARN-509), in which TAK-700 is the most advanced. TAK-700 is a selective inhibitor of 17, 20 lyase for production of steroidal hormone (Chart 1). By mechanism of action, it is a more specific 17, 20 lyase inhibitor Though there is a high chance that Zytiga patent will get extension beyond 2020, TAK-700 profile. TAK-700 will be the treatment of choice in patients who.. PhIII data of TAK-700 in mCRPC patients is due in 2H 2013. Table 3 highlights the expected key events which have the potential to change the current treatment paradigm of prostate cancer.
TAK-700 vs. Approved anti Androgen therapy (Table 5, 6): How is TAK-700 different from Zytiga (Table1) in its mechanism of Action? Has this differentiation been revealed in reported clinical trial data?
Tables Included:
Table 1: Comparison of CY17Inhibitors Pipeline Drugs Acting On Androgen Synthesis
Table 2: Key Candidates Of Anti Androgen Therapy In Prostate Cancer
Table 3: Upcoming Milestones- TAK-700
Table 4: Reported Clinical Data of TAK-700
Table 5 Clinical Data Comparision- TAK-700 vs. Zytiga vs. TOK-001
Table 6: Clinical Data Comparision- TAK- 700 vs. Xtandi vs. ARN-509 vs ODM-201
Table 7: Prostate cancer –Market dynamics year 2016 and beyond
Table 8: TAK-700- Ongoing Clinical trials
In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed a paradigm shift due to the launch of various new drugs (Jevtana, Zytiga, Xtandi, Provenge). There are also a number of new candidates in late stage development to hit this market through different pathways. In the pipeline (Table 2), ~4 drugs are in late stage clinical development to compete against both these molecules (TAK-700, TOK-001, ODM-021, ARN-509), in which TAK-700 is the most advanced. TAK-700 is a selective inhibitor of 17, 20 lyase for production of steroidal hormone (Chart 1). By mechanism of action, it is a more specific 17, 20 lyase inhibitor Though there is a high chance that Zytiga patent will get extension beyond 2020, TAK-700 profile. TAK-700 will be the treatment of choice in patients who.. PhIII data of TAK-700 in mCRPC patients is due in 2H 2013. Table 3 highlights the expected key events which have the potential to change the current treatment paradigm of prostate cancer.
TAK-700 vs. Approved anti Androgen therapy (Table 5, 6): How is TAK-700 different from Zytiga (Table1) in its mechanism of Action? Has this differentiation been revealed in reported clinical trial data?
Tables Included:
Table 1: Comparison of CY17Inhibitors Pipeline Drugs Acting On Androgen Synthesis
Table 2: Key Candidates Of Anti Androgen Therapy In Prostate Cancer
Table 3: Upcoming Milestones- TAK-700
Table 4: Reported Clinical Data of TAK-700
Table 5 Clinical Data Comparision- TAK-700 vs. Zytiga vs. TOK-001
Table 6: Clinical Data Comparision- TAK- 700 vs. Xtandi vs. ARN-509 vs ODM-201
Table 7: Prostate cancer –Market dynamics year 2016 and beyond
Table 8: TAK-700- Ongoing Clinical trials
